Newstral
Article
Bbarrons.com on 2022-01-07 21:47
Biogen’s Alzheimer’s Drug Has Another Shot at Success3 min read
Related news
- BBiogen’s Alzheimer’s Drug Has Another Shot at Success3 min readbarrons.com
- BAnother Setback for Biogen’s Controversial Alzheimer’s Drug1 min readbarrons.com
- Biogen’s controversial Alzheimer’s drug made $1.6M in revenue in JuneNew York Post
- MWhat to know about the Alzheimer’s drug data coming out this week3 min readmarketwatch.com
- MBiogen’s FDA-approved Alzheimer’s drug, first new remedy in almost twenty yearsmvtelegraph.com
- MBiogen’s controversial Alzheimer’s drug generates $2 million gross sales in first few weeks after approvalmvtelegraph.com
- BBiogen After the Alzheimer’s Drug Debacle: Time to Sell the Parts? 4 min readbarrons.com
- FDA approves Biogen’s controversial Alzheimer’s drugNew York Post
- MBiogen’s Alzheimer’s Drug May Price Medicare Billions of {Dollars} Yearly: Reportmvtelegraph.com
- FBiogen’s Alzheimer’s drug shows early promiseft.com
- Report Biogen’s Alzheimer’s drug shows early promiseReuters
- IDr. Karlawish on Biogen’s Alzheimer’s drug approval: ‘another study is needed’invezz.com
- BBiogen’s Alzheimer Drug Sales Were Dismal. Earnings Are Lifting the Stock.3 min readbarrons.com
- MThird member of the celebrated FDA panel resigns as a result of approval of Biogen’s Alzheimer’s drugmvtelegraph.com
- BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min readbarrons.com
- BBiogen’s Alzheimer’s Drug Won’t Get Approved, Analyst Saysbarrons.com
- Biogen’s $56 000 Alzheimer’s drug evades Biden’s cost curbspressherald.com